Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 24;13:1649–1659. doi: 10.2147/OTT.S231153

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

PTEN was a direct target of miR-486-5p. (A) Sequence alignment of miR-586-5p with the putative binding sites within the WT or MT regions of PTEN. (B, C) The luciferase activity in PANC-1 cells following co-transfecting with PTEN-WT/MT 3ʹ-UTR plasmid and miR-486-5p agonist was detected using dual luciferase reporter assay. (D) The luciferase activity in PANC-1 cells following co-transfecting with PTEN-WT/MT 3ʹ-UTR plasmid and miR-486-5p antagonist was detected using dual luciferase reporter assay. (E) PANC-1 cells were transfected with miR-486-5p antagonist for 48 hrs. RT-qPCR was used to detect the level of PTEN in PANC-1 cells. **P<0.01 vs control group.